Press releaseGlobe Newswire
Mink Therapeutics
INKT · NASDAQ
$9.86+$0.30 (+3.14%)TodayMarket closed ·
Prev close $9.56
Latest news
- News
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
- Press releaseGlobe Newswire
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
- Press releaseGlobe Newswire
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
- Press releaseBusiness Wire
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
- Press releaseGlobe Newswire
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
- Press releasePRNewswire
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
- Press releaseGlobe Newswire
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
- Press releaseBusiness Wire
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
- Press releaseBusiness Wire
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
- Press releaseBusiness Wire
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
- News
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
Earnings Scheduled For May 15, 2026
- Press releaseBusiness Wire
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
- News
Earnings Scheduled For March 31, 2026
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Market-Moving News for March 10th
- Press releaseBusiness Wire
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology
- NewsAvi Kapoor
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- News
MiNK Therapeutics's Earnings Outlook
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
- NewsAvi Kapoor
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
- News
Examining the Future: MiNK Therapeutics's Earnings Outlook
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.